These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 23392600)
1. [Personalized medicine in cytokine-targeted therapy]. Behrens F; Köhm M Z Rheumatol; 2013 Feb; 72(1):41-8. PubMed ID: 23392600 [TBL] [Abstract][Full Text] [Related]
2. [Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy]. Feist E; Dörner T Z Rheumatol; 2013 Feb; 72(1):49-58. PubMed ID: 23223871 [TBL] [Abstract][Full Text] [Related]
3. [Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs]. Fiehn C; Keyßer G; Lorenz HM Z Rheumatol; 2013 Feb; 72(1):27-40. PubMed ID: 23247868 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics: implications for therapy in rheumatic diseases. Davila L; Ranganathan P Nat Rev Rheumatol; 2011 Aug; 7(9):537-50. PubMed ID: 21826093 [TBL] [Abstract][Full Text] [Related]
6. Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. Kringelbach TM; Glintborg B; Hogdall EV; Johansen JS; Hetland ML; BMJ Open; 2018 Feb; 8(2):e019325. PubMed ID: 29391382 [TBL] [Abstract][Full Text] [Related]
7. [Personalized medicine in rheumatology]. Szekanecz Z Orv Hetil; 2013 Mar; 154(13):483-96. PubMed ID: 23524232 [TBL] [Abstract][Full Text] [Related]
8. Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. Balevic SJ; Sagcal-Gironella ACP Rheum Dis Clin North Am; 2022 Feb; 48(1):305-330. PubMed ID: 34798954 [TBL] [Abstract][Full Text] [Related]
9. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going? Maini RN Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377 [TBL] [Abstract][Full Text] [Related]
10. Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors? Sutcliffe M; Radley G; Barton A Expert Rev Clin Immunol; 2020 Apr; 16(4):389-396. PubMed ID: 32176556 [No Abstract] [Full Text] [Related]
12. Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. Ferraccioli G; De Santis M; Tolusso B Pharmacogenomics; 2004 Dec; 5(8):1107-16. PubMed ID: 15584877 [TBL] [Abstract][Full Text] [Related]
13. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Schub D; Assmann G; Sester U; Sester M; Schmidt T Arthritis Res Ther; 2018 Nov; 20(1):252. PubMed ID: 30413189 [TBL] [Abstract][Full Text] [Related]
14. New cytokine targets in inflammatory rheumatic diseases. Connell L; McInnes IB Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211 [TBL] [Abstract][Full Text] [Related]
15. Era of biosimilars in rheumatology: reshaping the healthcare environment. Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050 [TBL] [Abstract][Full Text] [Related]
16. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Gabay C; McInnes IB Arthritis Res Ther; 2009; 11(3):230. PubMed ID: 19519923 [TBL] [Abstract][Full Text] [Related]
17. Advances in targeted therapies XII. Preface. Breedveld FC; Kalden JR; Smolen JS Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1. PubMed ID: 21339210 [No Abstract] [Full Text] [Related]
19. What is the future of targeted therapy in rheumatology: biologics or small molecules? Mócsai A; Kovács L; Gergely P BMC Med; 2014 Mar; 12():43. PubMed ID: 24620738 [TBL] [Abstract][Full Text] [Related]
20. Proceedings of the XIIth International Symposium on Advances in Targeted Therapies. April 14-18, 2010. Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1-122. PubMed ID: 21438187 [No Abstract] [Full Text] [Related] [Next] [New Search]